Bildkälla: Stockfoto

Initiator Pharma: The Initiation of Phase IIb Study with IPED2015 - Redeye

Initiator Pharma announced today that it has dosed the first patient in the Phase IIb study of its main Erectile Dysfunction (ED) treatment candidate, IPED2015. This is an important milestone for the company and shows that the development of the drug is progressing according to plan.

Initiator Pharma announced today that it has dosed the first patient in the Phase IIb study of its main Erectile Dysfunction (ED) treatment candidate, IPED2015. This is an important milestone for the company and shows that the development of the drug is progressing according to plan.
Börsvärldens nyhetsbrev
ANNONSER